Infliximab in chronic myelogenous leukemia.
Mittre
Hervé
H
Marcelli
Christian
C
Leporrier
Michel
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000069285:Infliximab; D007275:Injections, Intravenous; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000188:drug therapy*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000069285:Infliximab; D016044:Fusion Proteins, bcr-abl; D008727:Methotrexate